Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs

Am J Hematol. 2016 Oct;91(10):E455-6. doi: 10.1002/ajh.24454. Epub 2016 Jul 14.

Authors

Emilie Chalayer¹, Céline Chapelle^{2

3}, Xavier Leleu⁴, Ismail Elalamy⁵, Silvy Laporte^{6

2

3}, Bernard Tardy^{6

2

3}

Affiliations

¹ Centre d'investigation Clinique CIC 1408, CHU Saint Etienne, France. [email protected].
² Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, France.
³ INSERM UMR 1059, Equipe DVH, Université J Monnet, Saint Etienne, France.
⁴ Service d'hématologie clinique, CHU de Poitiers, France.
⁵ Hôpital Tenon, APHP, France.
⁶ Centre d'investigation Clinique CIC 1408, CHU Saint Etienne, France.

PMID: 27341647
DOI: 10.1002/ajh.24454

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Humans
Immunomodulation / genetics*
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy*
Risk Factors
Venous Thromboembolism / drug therapy*
Venous Thromboembolism / pathology